Overview

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and effectiveness of the intetumumab, alone and in combination with dacarbazine, in patients with stage 4 melanoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Centocor, Inc.

Collaborator:

Janssen-Cilag Farmaceutica, S.R.L.

Treatments:

Antibodies, Monoclonal
Dacarbazine
Intetumumab